GeNeuro and Karolinska Institute collaborate in multiple sclerosis
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Tecentriq-Avastin combo hits endpoint in liver cancer
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics bags 37.3m in Series B financing round
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (34.4m).
GHO capital launches EU’s largest fund ever for life sciences
GHO Capital raises 975m in largest ever European private equity healthcare fund.
Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Novo secures Dicernas RNAi liver assets
Danish Novo Nordisk A/S has secured access to Dicerna Incs GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
EU with poor success in fighting superbugs
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Cellectis presents way to safer CAR-Ts
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
Update: BIO-Europe growing further
Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Magenta Therapeutics exercises ATAC licence option
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AGs anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).